Tositumomab and Iodine I 131 Tositumomab (Bexaar)

References

1. 1.↵
   1. Rutar FJ,
   2. Augustine SC,
   3. Kaminski MS,
   4. et al

   . Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. Clin Lymphoma 2001;2:164–72

   PubMedWeb of Science
2. 2.↵
   1. Kaminski MS,
   2. Zelenetz AD,
   3. Press OW,
   4. et al

   . Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918–28

   Abstract/FREE Full Text
3. 3.↵
   1. Kaminski MS,
   2. Estes J,
   3. Zasadny KR,
   4. et al

   . Radioimmunotherapy with iodine (131) I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259–66

   Abstract/FREE Full Text
4. 4.↵
   1. Davies AJ

   . A review of tositumomab and I (131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma. Expert Opin Biol Ther 2005;5:577–88

   CrossRefPubMed
5. 5.↵
   1. Kaminski MS,
   2. Tuck M,
   3. Estes J,
   4. et al

   . 131 I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441–49

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Davies AJ

   . Tositumomab and iodine [131I] tositumomab in the management of follicular lymphoma: an oncologist's view. Q J Nucl Med Mol Imaging 2004;48:305–16

   PubMed
7. 7.↵
   1. Kaminski MS,
   2. Radford JA,
   3. Gregory SA,
   4. et al

   . Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol 2005;23:7985–93

   Abstract/FREE Full Text
8. 8.↵
   1. Davies AJ,
   2. Rohatiner AZ,
   3. Howell S,
   4. et al

   . Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004;22:1469–79

   Abstract/FREE Full Text
9. 9.↵
   1. Kaminski M

   . Bexxar, iodine I 131 tositumomab, effective in long-term follow-up of non-Hodgkin's lymphoma. Cancer Biol Ther 2007;6:996–97

   PubMed
10. 10.↵
    1. Smith S,
    2. Sweetenham JW

    . Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma. Future Oncol 2007;3:255–62

    CrossRefPubMed
11. 11.↵
    1. Dosik AD,
    2. Coleman M,
    3. Kostakoglu L,
    4. et al

    . Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer 2006;106:616–22

    CrossRefPubMed
12. 12.↵
    1. William BM,
    2. Bierman PJ

    . I-131 tositumomab. Expert Opin Biol Ther 2010;10:1271–78

    CrossRefPubMed
13. 13.↵
    1. Cheung MC,
    2. Maceachern JA,
    3. Haynes AE,
    4. et al

    . I-tositumomab in lymphoma. Curr Oncol 2009;16:32–47

    PubMed